JP7750884B2 - HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 - Google Patents
HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法Info
- Publication number
- JP7750884B2 JP7750884B2 JP2022578935A JP2022578935A JP7750884B2 JP 7750884 B2 JP7750884 B2 JP 7750884B2 JP 2022578935 A JP2022578935 A JP 2022578935A JP 2022578935 A JP2022578935 A JP 2022578935A JP 7750884 B2 JP7750884 B2 JP 7750884B2
- Authority
- JP
- Japan
- Prior art keywords
- lenvatinib
- hif
- rcc
- inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042307P | 2020-06-22 | 2020-06-22 | |
| US63/042,307 | 2020-06-22 | ||
| US202163146915P | 2021-02-08 | 2021-02-08 | |
| US63/146,915 | 2021-02-08 | ||
| PCT/US2021/038172 WO2021262563A1 (en) | 2020-06-22 | 2021-06-21 | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531675A JP2023531675A (ja) | 2023-07-25 |
| JP2023531675A5 JP2023531675A5 (cg-RX-API-DMAC7.html) | 2024-06-27 |
| JP7750884B2 true JP7750884B2 (ja) | 2025-10-07 |
Family
ID=79281740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578935A Active JP7750884B2 (ja) | 2020-06-22 | 2021-06-21 | HIF-2α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210838A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4168008B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7750884B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230026493A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115803629A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021296151A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026094A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183852A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3072250T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022016406A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021262563A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
| US20240327929A1 (en) * | 2021-08-12 | 2024-10-03 | Merck Sharp & Dohme Llc | Dosage regimen for administration of belzutifan |
| EP4425678A1 (en) | 2023-02-28 | 2024-09-04 | LG Energy Solution, Ltd. | Separator for electrochemical device and electrochemical device comprising same |
| JPWO2024204679A1 (cg-RX-API-DMAC7.html) * | 2023-03-31 | 2024-10-03 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| EP3866927A4 (en) * | 2018-10-17 | 2022-07-27 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
-
2021
- 2021-06-21 JP JP2022578935A patent/JP7750884B2/ja active Active
- 2021-06-21 CN CN202180049537.5A patent/CN115803629A/zh active Pending
- 2021-06-21 KR KR1020237002565A patent/KR20230026493A/ko active Pending
- 2021-06-21 MX MX2022016406A patent/MX2022016406A/es unknown
- 2021-06-21 ES ES21828761T patent/ES3072250T3/es active Active
- 2021-06-21 US US18/009,115 patent/US20230210838A1/en active Pending
- 2021-06-21 EP EP21828761.3A patent/EP4168008B1/en active Active
- 2021-06-21 BR BR112022026094A patent/BR112022026094A2/pt unknown
- 2021-06-21 EP EP26162704.6A patent/EP4775271A2/en active Pending
- 2021-06-21 CA CA3183852A patent/CA3183852A1/en active Pending
- 2021-06-21 WO PCT/US2021/038172 patent/WO2021262563A1/en not_active Ceased
- 2021-06-21 AU AU2021296151A patent/AU2021296151A1/en active Pending
-
2022
- 2022-12-16 MX MX2025014865A patent/MX2025014865A/es unknown
Non-Patent Citations (2)
| Title |
|---|
| Eisai and Merck Receive Breakthrough Therapy Designation from FDA fo r LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as Combinat ion Therapy for Advanced and/or Metastatic Renal Cell Carcinoma, 2018年1 月9日, [retrieved on 2024. 8. 7], Retrieved from the Internet: <https:// www.merck.com/news/eisai-and-merck-receive-breakthrough-therapy-designat ion-from-fda-for-lenvima-lenvatinib-mesylate-and-keytruda-pembrolizumabas-combination-therapy-for-advanced-and-or-metastatic-rena/> |
| The NEW ENGLAND JOURNAL of MEDICINE, 2021, Vol. 385, No. 22, pp. 203 6-2046 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022016406A (es) | 2023-01-30 |
| MX2025014865A (es) | 2026-01-07 |
| EP4168008A4 (en) | 2024-08-07 |
| EP4775271A2 (en) | 2026-07-15 |
| BR112022026094A2 (pt) | 2023-01-17 |
| CN115803629A (zh) | 2023-03-14 |
| ES3072250T3 (en) | 2026-06-30 |
| JP2023531675A (ja) | 2023-07-25 |
| AU2021296151A1 (en) | 2023-02-02 |
| KR20230026493A (ko) | 2023-02-24 |
| EP4168008A1 (en) | 2023-04-26 |
| EP4168008B1 (en) | 2026-03-18 |
| CA3183852A1 (en) | 2021-12-30 |
| WO2021262563A1 (en) | 2021-12-30 |
| US20230210838A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| Samol et al. | Safety and tolerability of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study | |
| WO2018156812A1 (en) | Treatment of egfr-driven cancer with fewer side effects | |
| CN115845070A (zh) | 用notch和pd-1或pd-l1抑制剂的组合治疗 | |
| Hedayat et al. | Selumetinib: a selective MEK1 inhibitor for solid tumor treatment | |
| US20230181565A1 (en) | Crenolanib combination therapy | |
| JP2022551652A (ja) | 線維芽細胞増殖因子受容体シグナル伝達の調節不全を伴う癌の標的処置 | |
| AU2018380174A1 (en) | Use of PARP inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| WO2018170457A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| Mita et al. | Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors | |
| JP2023524789A (ja) | Tno155及びナザルチニブを含む医薬組合せ | |
| JP2025156341A (ja) | PD-1アンタゴニスト、HIF-2α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| Mehnert et al. | A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors | |
| WO2020236668A1 (en) | Leukadherin-1 alone or in combination for use in the treatment of cancer | |
| JP7571024B2 (ja) | 抗ccr4抗体抵抗性のがんの治療剤 | |
| RU2858600C2 (ru) | Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли | |
| WO2021262562A2 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| JP7308145B2 (ja) | 固形腫瘍を治療するための医薬組成物 | |
| HK40087480A (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib | |
| Sharma et al. | New and potential therapies for the treatment of breast cancer: An update for oncologists | |
| JP2020510058A (ja) | トリフルリジン/チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物 | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer | |
| JP2024531653A (ja) | 固形腫瘍の処置のための経口投与パクリタキセル、P-gp阻害剤、およびチェックポイント阻害剤の治療的組み合わせ | |
| US20210113692A1 (en) | Dosing regimen | |
| Bocci et al. | Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240619 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240820 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250613 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250826 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250925 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7750884 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |